A Phase 3 interventional study of Bumetanide and Furosemide in Cirrhosis, sponsored by Stacy Johnson. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Stacy Johnson · Phase 3, Interventional, and Treatment
Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis.
Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.
1,270 studies on the registry are indexed under Fibrosis; 276 are open to participants now.
This study's planned enrollment of 500 is above the median of 63 across 840 interventional studies indexed under Fibrosis.
Browse Fibrosis studies →This is the only study on the registry with Stacy Johnson as lead sponsor.
Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Bumetanide
Drug: Furosemide
Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders
Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders
Percent change in weight
Percent change in weight measured in kilograms from date of emergency department presentation (Day 0) to Day 7 of hospitalization, or date of discharge, whichever is earlier
Time frame: 7 days
Development of acute kidney injury
Stage 2 or higher acute kidney injury developing within 14 days of presentation to emergency department in accordance with KDIGO criteria
Time frame: 14 days
Need for replacement therapy
New initiation of intermittent or continuous hemodialysis within 14 days of presentation to the emergency department
Time frame: 14 days
Severe electrolyte derangement
New decrease in serum potassium to less than 2.5 mEq/L within 14 days of presentation to the emergency department
Time frame: 14 days
Hospital length of stay
Time from initial presentation to the emergency department to the time of discharge from the hospital or time of death, if a subject dies within the hospital
Time frame: 30 days
Unplanned hospital readmission
Readmission to the hospital for an unexpected reason within 30 days of a prior hospital admission
Time frame: 30 days
30-day mortality
Death occurring within the 30 days following presentation to the emergency department and subsequent hospital admission
Time frame: 30 days
Plan to share: Yes — Findings from the study will be presented at one or more scientific conferences. Results will be submitted for publication to a peer-reviewed journal. Data will be made available to other researchers after publication upon request and local institutional approval.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Following publication of manuscript
Access criteria: Written request and local institutional approval
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Mar 2029, 32 months after the start.
Of 52 phase 3 interventional studies under Fibrosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's planned 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bumetanide · Furosemide